Compare BZUN & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZUN | PRQR |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | China | Netherlands |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.7M | 185.4M |
| IPO Year | N/A | 2014 |
| Metric | BZUN | PRQR |
|---|---|---|
| Price | $2.20 | $1.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 192.1K | ★ 285.7K |
| Earning Date | 03-25-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.10 | $11.37 |
| Revenue Next Year | $3.93 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.12 | $1.08 |
| 52 Week High | $4.88 | $3.10 |
| Indicator | BZUN | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 27.06 | 44.87 |
| Support Level | N/A | $1.33 |
| Resistance Level | $3.05 | $2.27 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 11.27 | 19.00 |
Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including strategy and tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.